Insmed
INSM
158 hedge funds and large institutions have $2.39B invested in Insmed in 2019 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 48 increasing their positions, 49 reducing their positions, and 11 closing their positions.
291% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 11
121% more capital invested
Capital invested by funds: $1.08B → $2.39B (+$1.31B)
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
25% more funds holding
Funds holding: 126 → 158 (+32)
20% more call options, than puts
Call options by funds: $25.2M | Put options by funds: $21M
0.9% less ownership
Funds ownership: 106.95% → 106.05% (-0.9%)
2% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 49
Top Buyers
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$30.3M |
| 2 |
D.E. Shaw & Co
New York
|
+$13.4M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$9.59M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$8.76M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$8.51M |
Top Sellers
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
-$21.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$20.5M |
| 3 |
NC
Nexthera Capital
New York
|
-$14.4M |
| 4 |
AI
Atom Investors
Austin,
Texas
|
-$12.5M |
| 5 |
State Street
Boston,
Massachusetts
|
-$12.2M |
INSM Hedge Fund Activity: Q1 2019 in Review
158 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q1 2019, worth a combined $2.39B — up 121% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new INSM positions and 11 closed out — a net gain of 32 holders — while 48 added to existing stakes and 49 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $30.3M. The largest seller was VOYA Investment Management, cutting an estimated $21.9M.
- 158 institutional investors held Insmed (INSM) as of Q1 2019, up from 126 in Q4 2018.
- Funds reported $2.39B of Insmed stock for Q1 2019, up 121% quarter-over-quarter.
- 43 funds opened new Insmed positions in Q1 2019 and 11 closed out, a net change of +32 holders.
- The largest Insmed buyer in Q1 2019 was Vivo Capital, an estimated $30.3M added.
- The largest Insmed seller in Q1 2019 was VOYA Investment Management, an estimated $21.9M sold.
Based on aggregated 13F filings for Q1 2019.